Audrey E. Greenberg

Audrey Greenberg is a visionary leader in biotech, pharma services, and investment strategy, known for scaling companies, structuring complex transactions, and driving industry transformation. As Founder and Chief Business Officer of the Center for Breakthrough Medicines (CBM), she built the company from inception to a multi-billion-dollar enterprise, securing $500 million+ in capital, expanding operations to 350,000+ square feet of GMP manufacturing space, and leading its strategic acquisition by SK pharmteco.

With a background in private equity, investment banking, and real estate, Audrey has managed $10 billion+ in assets, executed high-profile M&A deals, and positioned companies for IPOs and strategic exits. She now leads AG Capital Advisors, advising biotech and healthcare companies on capital allocation, operational scale-up, and global expansion.

A respected board director, Audrey serves on the boards of New York Mortgage Trust, NLS Pharma, ZSX Medical, the Alliance for Regenerative Medicine, Phacilitate, Ben Franklin Technology Partners, Greater Philadelphia Chamber of Commerce, King of Prussia Business District, and the Innovation Advisory Board at the Abramson Cancer Center at Penn Medicine.  She also plays a key role in Philadelphia’s biotech ecosystem, working to attract investment, talent, and innovation to the region.

A Wharton MBA and CPA, Audrey’s leadership and contributions to the industry have been widely recognized, earning her prestigious honors, including Titan 100 (three-time honoree & Hall of Fame inductee), Most Influential Philadelphian (twice), Philly Power 100, Healthcare Power Player, Medicine Maker Power List, Power Woman, Women of Influence, Leader of the Year, Top Revolutionary Trailblazer, and Young All-Star. Under her leadership, CBM was also honored with awards such as Employer of the Year, Tech Translator of the Year, DEI Initiative of the Year, Deal of the Year (twice), Startup of the Year, and Innovator of the Year. A sought-after speaker and mentor, she champions biotech innovation, AI-driven drug development, and the intersection of finance and life sciences.